Core Viewpoint - MBX Biosciences, Inc. has appointed Karen Basbaum as Chief Business Officer, bringing over 20 years of experience in corporate strategy and business development within the biotechnology and pharmaceutical sectors [1][3]. Company Overview - MBX Biosciences is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders [1][5]. - The company utilizes its proprietary PEP™ platform to advance a pipeline of candidates targeting significant unmet medical needs [5]. Leadership Appointment - Karen Basbaum's extensive background includes leading strategic partnerships and corporate transactions valued at over $10 billion during her tenure at Poseida Therapeutics [3][4]. - Her previous roles include senior positions at DNAtrix, Dauntless Pharmaceuticals, and Elcelyx Therapeutics, contributing to major corporate transactions, including a $7 billion acquisition by Bristol Myers Squibb [4]. Pipeline Development - MBX's pipeline includes canvuparatide (MBX 2109) for chronic hypoparathyroidism, which is preparing for Phase 3 development, and an obesity portfolio with candidates in various stages of development [5]. - The company is also advancing imapextide (MBX 1416) for post-bariatric hypoglycemia, currently in Phase 2 development [5].

Core Insights - MBX Biosciences is on track to initiate Phase 3 trials for canvuparatide in Q3 2026 after a successful End-of-Phase 2 meeting with the FDA [1][2] - Canvuparatide aims to establish a new standard of care for chronic hypoparathyroidism by providing a once-weekly dosing regimen that restores physiologic PTH activity [2] - The Phase 3 trial will enroll approximately 160 patients and will include a double-blind placebo-controlled design [3] Company Overview - MBX Biosciences is a clinical-stage biopharmaceutical company focused on precision peptide therapies for endocrine and metabolic disorders [1][7] - The company utilizes its proprietary Precision Endocrine Peptide™ (PEP™) platform technology to develop novel therapies [5][7] - The pipeline includes canvuparatide for chronic hypoparathyroidism, an obesity portfolio, and imapextide for post-bariatric hypoglycemia [8] Product Details - Canvuparatide is a parathyroid hormone peptide prodrug designed for long-acting hormone replacement therapy [5] - It has received orphan drug designation from both the FDA and the European Medicines Agency for the treatment of chronic hypoparathyroidism [4][5] - The treatment aims to provide continuous PTH exposure with lower daily peak-to-trough ratios compared to daily PTH dosing regimens [5] Disease Context - Chronic hypoparathyroidism is a rare endocrine disease affecting over 250,000 individuals in the U.S. and Europe, characterized by low calcium levels due to PTH deficiency [6] - Current treatments primarily involve high doses of oral calcium and active vitamin D supplements, which do not address the underlying PTH deficiency [6]

Core Insights - MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on precision peptide therapies for endocrine and metabolic disorders [1][3] - The company has an upcoming schedule of investor conferences in March 2026, where key executives will participate [2] Company Overview - MBX Biosciences specializes in the discovery, development, and commercialization of novel precision peptide therapies using its proprietary PEP™ platform [3] - The company is advancing a pipeline that includes canvuparatide (MBX 2109) for chronic hypoparathyroidism, which is preparing for Phase 3 development [3] - The obesity portfolio includes MBX 4291 in Phase 1 development and multiple discovery and pre-clinical candidates [3] - Imapextide (MBX 1416) is in Phase 2 development for post-bariatric hypoglycemia [3] - The company is based in Carmel, Indiana [3]

Core Insights - MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on precision peptide therapies for endocrine and metabolic disorders [1][3] - The company will participate in two upcoming investor conferences, providing opportunities for engagement with investors [2] Company Overview - MBX Biosciences specializes in the discovery, development, and commercialization of novel precision peptide therapies using its proprietary PEP™ platform [3] - The company is advancing a pipeline that includes canvuparatide (MBX 2109) for chronic hypoparathyroidism, which is preparing for Phase 3 development [3] - The obesity portfolio includes MBX 4291 in Phase 1 development and several discovery and pre-clinical candidates [3] - Imapextide (MBX 1416) is in Phase 2 development for post-bariatric hypoglycemia [3] - The company is based in Carmel, Indiana [3]

Core Insights - MBX Biosciences, Inc. has appointed Laurie Stelzer as an independent director and chairperson of the audit committee, bringing extensive executive and financial leadership experience [1][2] - The company is focused on developing precision peptide therapies for endocrine and metabolic disorders, with a strong pipeline and a catalyst-rich year ahead [2][3] Company Overview - MBX Biosciences specializes in the discovery, development, and commercialization of novel precision peptide therapies using its proprietary PEP™ platform [3] - The company is advancing a pipeline that includes canvuparatide (MBX 2109) for chronic hypoparathyroidism, an obesity portfolio with MBX 4291 in Phase 1, and imapextide (MBX 1416) for post-bariatric hypoglycemia in Phase 2 [3] Leadership and Governance - Laurie Stelzer has over 25 years of experience in finance and leadership roles across various biopharmaceutical companies, including previous positions as CFO at multiple firms [2] - Stelzer's expertise is expected to enhance the company's governance and strategic direction as it progresses through clinical trials [2]

Company Overview - MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel precision peptide therapies for endocrine and metabolic disorders [3] - The company is based in Carmel, Indiana and utilizes its proprietary PEP™ platform for drug discovery [3] Pipeline Development - MBX Biosciences is advancing a pipeline that includes canvuparatide (MBX 2109) for chronic hypoparathyroidism, which is preparing for Phase 3 development [3] - The obesity portfolio includes MBX 4291, currently in Phase 1 development, along with multiple discovery and pre-clinical candidates [3] - Imapextide (MBX 1416) is in Phase 2 development for post-bariatric hypoglycemia [3] Upcoming Events - Kent Hawryluk, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026 [1] - The company presentation is scheduled for January 13, 2026, at 3:45 p.m. PT/6:45 p.m. ET [2] - A live webcast of the presentation will be available on the MBX Biosciences website, with a replay accessible for approximately 90 days [2]

Core Viewpoint - MBX Biosciences has submitted an Investigational New Drug (IND) application to the FDA for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug aimed at treating obesity, with a Phase 1 trial expected to start in Q3 2025 [2][3][4] Company Overview - MBX Biosciences is a clinical-stage biopharmaceutical company focused on developing novel precision peptide therapies for endocrine and metabolic disorders [6] - The company is based in Carmel, Indiana, and is advancing a pipeline that includes multiple candidates for obesity and other metabolic disorders [6] Product Details - MBX 4291 is designed as a once-monthly injectable treatment for obesity, potentially offering improved gastrointestinal tolerability and better adherence compared to existing treatments [3][4] - Preclinical studies indicate that MBX 4291 has a similar activity profile and body weight loss effect as tirzepatide, an approved weekly GLP-1/GIP co-agonist, with an extended duration of action [5] Development Pipeline - The company is advancing several early-stage obesity candidates alongside MBX 4291, utilizing its proprietary PEP™ platform to create precision peptides with differentiating characteristics [3][6] - Other candidates in the pipeline include canvuparatide (MBX 2109) in Phase 2 for chronic hypoparathyroidism and imapextide (MBX 1416) in Phase 1 for post-bariatric hypoglycemia [6] Proprietary Technology - MBX's PEP™ platform is designed to enhance peptide drug design, aiming to overcome limitations of traditional peptide therapies by optimizing pharmaceutical properties such as extended action profiles and consistent drug concentrations [7]